CAS 654671-78-0

Fosfato de sitagliptina

Descripción:

Fosfato de sitagliptina es un compuesto farmacéutico utilizado principalmente en el manejo de la diabetes mellitus tipo 2. Funciona como un inhibidor de la dipeptidil peptidasa-4 (DPP-4), lo que ayuda a aumentar la secreción de insulina y disminuir los niveles de glucagón en el torrente sanguíneo, mejorando así el control glucémico. La sustancia se administra típicamente por vía oral y a menudo se prescribe en combinación con otros medicamentos antidiabéticos. Fosfato de sitagliptina se caracteriza por su relativamente alta solubilidad en agua, lo que facilita su absorción en el tracto gastrointestinal. El compuesto tiene una estructura molecular específica que incluye un anillo de pirrolidina y un grupo fosfato, contribuyendo a su actividad biológica. Generalmente es bien tolerado, con un perfil de efectos secundarios que puede incluir trastornos gastrointestinales y un riesgo potencial de pancreatitis. Al igual que con cualquier medicamento, es importante que los pacientes consulten a profesionales de la salud para obtener asesoramiento personalizado y monitoreo mientras utilizan Fosfato de sitagliptina.

Fórmula: C₁₆H₁₅F₆N₅O·H₃O₄P

InChI: InChI=1S/C16H15F6N5O.H3O4P/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4)/t9-;/m1./s1

Clave InChI: InChIKey=IQFYVLUXQXSJJN-SBSPUUFOSA-N

SMILES: C(F)(F)(F)C=1N2C(CN(C(C[C@@H](CC3=C(F)C=C(F)C(F)=C3)N)=O)CC2)=NN1.P(=O)(O)(O)O

Sinónimos:

• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate
• 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate (1:1)
• 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1)
• 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate
• Glactiv
• Januvia
• Mk 0431
• Mk 431
• Sitagliptin Phosphate Intermediates
• Sitagliptin phosphate

(2R)​-​4-​Oxo-​4-​[3-​(trifluoromethyl)​-​5,​6-​dihydro-​[1,​2,​4]​triazolo[4,​3-​a]​pyrazin-​7(8H)​-​yl]​-​1-​(2,​4,​5-​trifluorophenyl)​butan-​2-​amine dihydrogen phosphate

CAS: 654671-78-0

Fórmula: C₁₆H₁₈F₆N₅O₅P

Pureza: 98%

Forma y color: Solid

Peso molecular: 505.3088

Ref: IN-DA003U9W

Sitagliptin Phosphate

CAS: 654671-78-0

Fórmula: C₁₆H₁₅F₆N₅O·H₃O₄P

Forma y color: White To Off-White Solid

Peso molecular: 407.32 97.99

Ref: 4Z-S-206

Sitagliptin phosphate

CAS: 654671-78-0

Sitagliptin phosphate

Pureza: 98%

Peso molecular: 505.31g/mol

Ref: 54-PC109238

Sitagliptin phosphate

CAS: 654671-78-0

Sitagliptin phosphate

Pureza: ≥98%

Peso molecular: 505.31g/mol

Ref: 54-BUP16033

Sitagliptin Phosphate

CAS: 654671-78-0

Fórmula: C₁₆H₁₅F₆N₅O·H₃PO₄

Pureza: >98.0%(T)(HPLC)

Forma y color: White to Light yellow powder to crystal

Peso molecular: 505.31

Ref: 3B-I1231

Sitagliptin phosphate

CAS: 654671-78-0

Sitagliptin phosphate (MK-0431 phosphate) is a dipeptidyl peptidase-4 (DPP4) inhibitor.

Fórmula: C₁₆H₁₈F₆N₅O₅P

Pureza: 99.72% - 99.91%

Forma y color: White Solid

Peso molecular: 505.31

Ref: TM-T23358

Sitagliptin Phosphate

Producto controlado

CAS: 654671-78-0

Applications Sitagliptin is a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has recently been approved for the therapy of type II diabetes.
References Kim, D., et al.: J. Med. Chem. 48, 141 (2005), Ahren, B., et al.: Eur. J. Pharmacol. 521 164 (2005), Bergman, A., et al: Clin. Ther. 28, 55 (2006)

Fórmula: C₁₆H₁₅F₆N₅O·H₃O₄P

Forma y color: Neat

Peso molecular: 505.31

Ref: TR-S491000

Sitagliptin Phosphate

CAS: 654671-78-0

Fórmula: C₁₆H₁₅F₆N₅OH₃PO₄

Peso molecular: 407.3 : 98.0

Ref: ST-EA-CP-S3041

(R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-α]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate anhydrous

CAS: 654671-78-0

(R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-α]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate anhydrous (TZP) is a drug candidate for the treatment of diabetes. TZP is a prodrug that is metabolized by the liver and gut to the active compound sitagliptin phosphate (SGP). TZP has been shown to reduce plasma glucose levels in diabetic rats. In vitro experiments have shown that TZP inhibits dipeptidyl peptidase IV (DPP-IV), which is an enzyme that degrades incretins such as glucagon like peptide 1 and glucose dependent insulinotropic polypeptide. These findings suggest that TZ

Fórmula: C₁₆H₁₅F₆N₅O•H₃O₄P

Pureza: Min. 98 Area-%

Forma y color: Powder

Peso molecular: 505.31 g/mol

Ref: 3D-FA10819